Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases

Journal of Neuro-Oncology

Volumn 125, Issue 1, 2015, Pages 149-156

  Kohutek, Zachary A ^a   Yamada, Yoshiya ^a   Chan, Timothy A ^a   Brennan, Cameron W ^a   Tabar, Viviane ^a   Gutin, Philip H ^a   Jonathan Yang, T ^a   Rosenblum, Marc K ^a   Ballangrud, Åse ^a   Young, Robert J ^a   Zhang, Zhigang ^a   Beal, Kathryn ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Brain; Metastasis; Necrosis; Radionecrosis; Radiosurgery; SRS

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BRAIN RADIOGRAPHY; BREAST CANCER; CANCER RADIOTHERAPY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; LINEAR ACCELERATOR; MAJOR CLINICAL STUDY; MALE; MELANOMA; MORBIDITY; MULTIVARIATE ANALYSIS; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCRIPTION; RADIATION NECROSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; STEREOTACTIC RADIOSURGERY; TREATMENT PLANNING; VERY ELDERLY; ADVERSE EFFECTS; AGE; ANALYSIS OF VARIANCE; BRAIN NEOPLASMS; COHORT ANALYSIS; KAPLAN MEIER METHOD; MIDDLE AGED; NECROSIS; PATHOLOGY; RADIATION INJURIES; RADIOSURGERY; SECONDARY; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BRAIN NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NECROSIS; RADIATION INJURIES; RADIOSURGERY; YOUNG ADULT;

EID: 84942985490     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1881-3     Document Type: Article

References (31)

1. Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Collette S, Collette L, Mueller RP (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29:134–141. doi:10.1200/JCO.2010.30.1655
2. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA, J Am Med Assoc 295:2483–2491. doi:10.1001/jama.295.21.2483
3. Korytko T, Radivoyevitch T, Colussi V, Wessels BW, Pillai K, Maciunas RJ, Einstein DB (2006) 12 Gy gamma knife radiosurgical volume is a predictor for radiation necrosis in non-AVM intracranial tumors. Int J Radiat Oncol Biol Phys 64:419–424. doi:10.1016/j.ijrobp.2005.07.980
4. Blonigen BJ, Steinmetz RD, Levin L, Lamba MA, Warnick RE, Breneman JC (2010) Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 77:996–1001. doi:10.1016/j.ijrobp.2009.06.006
5. Minniti G, Clarke E, Lanzetta G, Osti MF, Trasimeni G, Bozzao A, Romano A, Enrici RM (2011) Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol 6:48. doi:10.1186/1748-717X-6-48
6. Ohtakara K, Hayashi S, Nakayama N, Ohe N, Yano H, Iwama T, Hoshi H (2012) Significance of target location relative to the depth from the brain surface and high-dose irradiated volume in the development of brain radionecrosis after micromultileaf collimator-based stereotactic radiosurgery for brain metastases. J Neurooncol 108:201–209. doi:10.1007/s11060-012-0834-3
7. Schuttrumpf LH, Niyazi M, Nachbichler SB, Manapov F, Jansen N, Siefert A, Belka C (2014) Prognostic factors for survival and radiation necrosis after stereotactic radiosurgery alone or in combination with whole brain radiation therapy for 1–3 cerebral metastases. Radiat Oncol 9:105. doi:10.1186/1748-717X-9-105
8. Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, Farnan N (2000) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 47:291–298
9. Flickinger JC, Kondziolka D, Pollock BE, Maitz AH, Lunsford LD (1997) Complications from arteriovenous malformation radiosurgery: multivariate analysis and risk modeling. Int J Radiat Oncol Biol Phys 38:485–490
10. Miyawaki L, Dowd C, Wara W, Goldsmith B, Albright N, Gutin P, Halbach V, Hieshima G, Higashida R, Lulu B, Pitts L, Schell M, Smith V, Weaver K, Wilson C, Larson D (1999) Five year results of LINAC radiosurgery for arteriovenous malformations: outcome for large AVMS. Int J Radiat Oncol Biol Phys 44:1089–1106
11. Voges J, Treuer H, Sturm V, Buchner C, Lehrke R, Kocher M, Staar S, Kuchta J, Muller RP (1996) Risk analysis of linear accelerator radiosurgery. Int J Radiat Oncol Biol Phys 36:1055–1063
12. Nakamura JL, Verhey LJ, Smith V, Petti PL, Lamborn KR, Larson DA, Wara WM, McDermott MW, Sneed PK (2001) Dose conformity of gamma knife radiosurgery and risk factors for complications. Int J Radiat Oncol Biol Phys 51:1313–1319
13. Barker FG 2nd, Butler WE, Lyons S, Cascio E, Ogilvy CS, Loeffler JS, Chapman PH (2003) Dose-volume prediction of radiation-related complications after proton beam radiosurgery for cerebral arteriovenous malformations. J Neurosurg 99:254–263. doi:10.3171/jns.2003.99.2.0254
14. Mullins ME, Barest GD, Schaefer PW, Hochberg FH, Gonzalez RG, Lev MH (2005) Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. AJNR Am J Neuroradiol 26:1967–1972
15. Fatterpekar GM, Galheigo D, Narayana A, Johnson G, Knopp E (2012) Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum–use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI. AJR Am J Roentgenol 198:19–26. doi:10.2214/AJR.11.7417
16. Barajas RF, Chang JS, Sneed PK, Segal MR, McDermott MW, Cha S (2009) Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 30:367–372. doi:10.3174/ajnr.A1362
17. Gasparetto EL, Pawlak MA, Patel SH, Huse J, Woo JH, Krejza J, Rosenfeld MR, O’Rourke DM, Lustig R, Melhem ER, Wolf RL (2009) Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction. Radiology 250:887–896. doi:10.1148/radiol.2502071444
18. Enslow MS, Zollinger LV, Morton KA, Butterfield RI, Kadrmas DJ, Christian PE, Boucher KM, Heilbrun ME, Jensen RL, Hoffman JM (2012) Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma. Clin Nucl Med 37:854–861. doi:10.1097/RLU.0b013e318262c76a
19. Hatzoglou V, Ulaner GA, Zhang Z, Beal K, Holodny AI, Young RJ (2013) Comparison of the effectiveness of MRI perfusion and fluorine-18 FDG PET-CT for differentiating radiation injury from viable brain tumor: a preliminary retrospective analysis with pathologic correlation in all patients. Clin Imaging 37:451–457. doi:10.1016/j.clinimag.2012.08.008
20. Nedzi LA, Kooy H, Alexander E 3rd, Gelman RS, Loeffler JS (1991) Variables associated with the development of complications from radiosurgery of intracranial tumors. Int J Radiat Oncol Biol Phys 21:591–599
21. Varlotto JM, Flickinger JC, Niranjan A, Bhatnagar AK, Kondziolka D, Lunsford LD (2003) Analysis of tumor control and toxicity in patients who have survived at least one year after radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 57:452–464
22. Varlotto JM, Flickinger JC, Niranjan A, Bhatnagar A, Kondziolka D, Lunsford LD (2005) The impact of whole-brain radiation therapy on the long-term control and morbidity of patients surviving more than one year after gamma knife radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 62:1125–1132. doi:10.1016/j.ijrobp.2004.12.092
23. Kjellberg RN, Hanamura T, Davis KR, Lyons SL, Adams RD (1983) Bragg-peak proton-beam therapy for arteriovenous malformations of the brain. N Engl J Med 309:269–274. doi:10.1056/NEJM198308043090503
24. Flickinger JC, Lunsford LD, Kondziolka D, Maitz AH, Epstein AH, Simons SR, Wu A (1992) Radiosurgery and brain tolerance: an analysis of neurodiagnostic imaging changes after gamma knife radiosurgery for arteriovenous malformations. Int J Radiat Oncol Biol Phys 23:19–26
25. Lawrence YR, Li XA, el Naqa I, Hahn CA, Marks LB, Merchant TE, Dicker AP (2010) Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 76:S20–S27. doi:10.1016/j.ijrobp.2009.02.091
26. Chin LS, Ma L, DiBiase S (2001) Radiation necrosis following gamma knife surgery: a case-controlled comparison of treatment parameters and long-term clinical follow up. J Neurosurg 94:899–904. doi:10.3171/jns.2001.94.6.0899
27. Boothe D, Young R, Yamada Y, Prager A, Chan T, Beal K (2013) Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery. Neuro-oncology 15:1257–1263. doi:10.1093/neuonc/not085
28. Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Grewal J, Prabhu S, Loghin M, Gilbert MR, Jackson EF (2011) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79:1487–1495. doi:10.1016/j.ijrobp.2009.12.061
29. Belohlavek O, Simonova G, Kantorova I, Novotny J Jr, Liscak R (2003) Brain metastases after stereotactic radiosurgery using the Leksell gamma knife: can FDG PET help to differentiate radionecrosis from tumour progression? Eur J Nucl Med Mol Imaging 30:96–100. doi:10.1007/s00259-002-1011-2
30. Langleben DD, Segall GM (2000) PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 41:1861–1867
31. Memorial Sloan-Kettering Cancer Center; National Institutes of Health. 18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000—[cited 2014 Oct 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02037945. NLM Identifier: NCT02037945